United Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,260 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,260 shares of United Therapeutics Corporation stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $121.46, for a total transaction of $153,039.60. Following the completion of the sale, the chief executive officer now owns 1,400 shares in the company, valued at $170,044. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded down $0.23 on Monday, hitting $121.00. 190,600 shares of the stock traded hands, compared to its average volume of 569,661. United Therapeutics Corporation has a 52-week low of $112.01 and a 52-week high of $169.89. The stock has a market cap of $5,170.00, a PE ratio of 10.67 and a beta of 1.38.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The firm had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. During the same quarter in the prior year, the company earned $4.23 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. analysts anticipate that United Therapeutics Corporation will post 11.92 earnings per share for the current year.

WARNING: This article was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/13/united-therapeutics-corporation-uthr-ceo-martine-a-rothblatt-sells-1260-shares.html.

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Quantbot Technologies LP lifted its position in shares of United Therapeutics Corporation by 537.3% in the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 822 shares during the period. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of United Therapeutics Corporation in the 3rd quarter worth approximately $156,000. Eagle Global Advisors LLC purchased a new stake in shares of United Therapeutics Corporation in the 2nd quarter worth approximately $206,000. Toronto Dominion Bank lifted its position in shares of United Therapeutics Corporation by 244.7% in the 3rd quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 1,351 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. purchased a new stake in shares of United Therapeutics Corporation in the 3rd quarter worth approximately $233,000.

A number of analysts have issued reports on the stock. BidaskClub downgraded shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. ValuEngine downgraded shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. TheStreet downgraded shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. Zacks Investment Research upgraded shares of United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $132.82.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply